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Abstract: Uveitis is a potentially sight-threatening inﬂ  ammatory eye disease caused by multiple 
infectious and non-infectious etiologies for which the standard of care involves corticosteroids or 
various immunomodulary therapy (IMT) drugs. These available treatments, although effective, 
may cause signiﬁ  cant morbidity and sometimes mortality in uveitis patients due to their toxic 
side-effects and the necessity of long-term therapy to prevent recurrences. In order to avoid the 
systemic toxicity of corticosteroids and IMT or the repeated injections of local steroids necessary 
to control ocular inﬂ  ammation, and to prevent development of cumulative damage resulting from 
recurrent episodes of inﬂ  ammation, researchers have developed a number of local corticosteroid 
sustained-release devices that can be implanted directly into the vitreous of the eye, at the site 
of the inﬂ  ammatory disease. Preliminary studies of such a device, the ﬂ  uocinolone acetonide 
(Retisert™) implant, have shown signiﬁ  cant reductions in the number of inﬂ  ammatory episodes 
and decreased reliance on systemic corticosteroids or other IMT. This review explores the current 
research evaluating the ﬂ  uocinolone sustained-release intravitreal implant in the treatment of 
posterior uveitis and the implications for its future use on a wider scale.
Keywords: uveitis, immunomodulary therapy drugs, ﬂ  uocinolone acetonide implant, sustained-
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Introduction
Uveitis is an inﬂ  ammatory eye disease affecting the iris, ciliary body, and choroid 
that can lead to symptoms ranging from redness, pain, and blurred vision to markedly 
diminished acuity in the setting of severe or chronic disease (Opremcak et al 2004). 
Corticosteroids comprise the mainstay of uveitis therapy, but current methods of 
systemic, topical, and periocular administration can pose challenges to physicians 
and patients. Such difﬁ  culties have led investigators to explore new techniques for 
intraocular corticosteroid delivery, including dexamethasone devices and the sustained-
delivery ﬂ  uocinolone acetonide intravitreal implant (Retisert™, Bausch and Lomb, 
Rochester, NY, USA). The latter device has shown promise in several clinical trials, 
including pivotal trials that led to FDA approval of Retisert, and may become a long-
term alternative for patients suffering from posterior non-infectious uveitis.
Intraocular drug delivery systems: 
an ever-developing technology
The concept of intraocular drug-delivery systems is not novel to uveitis; such devices 
have already improved the treatment of cytomegalovirus retinitis in immunocom-
promised individuals. In a randomized trial, the intravitreal gancyclovir sustained-
release implant was shown to be superior to intravenous administration in preventing 
the progression of cytomegalvirus (CMV) retinitis in AIDS patients (Musch et al 
1997). The fellow eyes of implant patients showed higher rates of progression International Journal of Nanomedicine 2007:2(1) 56
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compared with patients given intravenous gancyclovir, 
however, and implant patients were also more likely to 
develop extraocular manifestations of CMV infection. A 
subsequent randomized trial demonstrated that the addition 
of oral gancyclovir to patients with the implant decreased 
the development of new cases of CMV retinitis, delayed 
progression of existing cases, and decreased the risk of 
Kaposi’s sarcoma (Martin et al 1999). The most common 
complication of gancyclovir implantation is vitreous hem-
orrhage, with an incidence of 10% (Dunn et al 2004). Less 
common complications include hypotony, uveitis, retinal 
detachment, choroidal effusion, and cataract.
The success of sustained-release delivery systems in the 
treatment of CMV retinitis led scientists to develop similar 
devices for use in patients with steroid-dependent chronic 
uveitis. In an experimental rabbit model of uveitis, Cheng 
et al (1995) demonstrated that an intravitreal sustained-
release dexamethasone implant was significantly more 
effective at controlling inﬂ  ammation by physical exam and 
objective measures than sham treatment of fellow eyes. In 
addition, implanted eyes had fewer instances of cataract, 
hypotony, and corneal neovascularization than fellow eyes. 
A case report describing implantation of a dexamethasone 
sustained-release device into a patient noted complete resolu-
tion of intraocular inﬂ  ammation for a 10-month period fol-
lowing surgery (Jaffe et al 2000b). After this time, however, 
the patient experienced recurrent disease suggesting that the 
dexamethasone was expended.
Uveitis: a challenging condition
to diagnose and manage
Classiﬁ  cation and epidemiology
Previous studies of the incidence and prevalence of uveitis 
in the United States estimated that 38 000 Americans were 
newly diagnosed each year, though a recent study by Gritz and 
Wong reports ﬁ  gures in Northern California that may require 
the national incidence to be re-examined (Foster and Vitale 
2002; Gritz and Wong 2004). In a 2004 study examining 
a large Health Maintenance Organization population, the 
incidence of uveitis was 52.4 per 100 000 person-years, with 
a prevalence of 115.3 per 100 000 (Gritz and Wong 2004). 
The age range of patients suffering from uveitis encompasses 
the entire lifespan, but mean ages from several studies 
were concentrated at 40 years with an approximately equal 
proportion of males and females affected and no particular 
racial tendencies (Foster and Vitale 2002). In the study of 
Northern California residents, however, women had a higher 
incidence and prevalence of uveitis, though only prevalence 
was statistically signiﬁ  cant (Gritz and Wong 2004). The 
broad disease entity of uveitis can be further classiﬁ  ed into 
the anatomical divisions of anterior, intermediate, posterior, 
and panuveitis (Foster and Vitale 2002).
Anterior uveitis primarily affects the iris, ciliary body, 
cornea, or sclera and usually has a non-infectious, and often 
idiopathic, etiology (Opremcak et al 2004). Overall, anterior 
uveitis is the most common form of uveitis, representing 
28%–61% of all cases (Foster and Vitale 2002).
Intermediate uveitis affects the anterior vitreous and 
pars plana, causing ﬂ  oaters and vision loss from cystoid 
macular edema (Opremcak et al 2004). Intermediate uveitis 
is responsible for the smallest proportion of overall cases, 
ranging from 3%–17% in different studies (Foster and Vitale 
2002). Most are idiopathic (69.1%), but common deﬁ  nable 
etiologies are sarcoidosis, 22.2%, multiple sclerosis, 8%, and 
Lyme disease, 0.6% (Foster and Vitale 2002).
Posterior uveitis involves the retina and choroid, 
making up 9.3%–38% of all uveitis cases (Foster and Vitale 
2002). Inﬂ  ammation of the retina and choroid results in 
decreased visual acuity and distorted vision with associated 
scotomata and ﬂ  oaters (Opremcak et al 2004). This form 
of uveitis accounts for more visual loss than other forms, 
often due to cystoid macular edema, retinal detachment, 
cataract, glaucoma, subretinal fibrosis, and optic disc 
atrophy (Sabrosa and Pavésio 2000). Posterior uveitis is 
often infectious, with toxoplasmosis representing 24.6% 
of cases and cytomegalovirus, 11.6%. Other etiologies are 
idiopathic, systemic lupus erythematosus (SLE), birdshot 
retinochoroidopathy, sarcoidosis, Adamantiades-Behcet’s 
disease (ABD), and syphilis (Foster and Vitale 2002).
Panuveitis affects all three sections of the uveal tract and 
is responsible for 7%–38% of all cases (Foster and Vitale 
2002). The most common cause is idiopathic (22.2%), 
followed by sarcoidosis, 14.1%, and multifocal choroiditis 
and panuveitis, 12.1%. Other causes include ABD, SLE, 
syphilis, Vogt-Koyanagi-Harada (VKH) syndrome, and 
sympathetic ophthalmia (Foster and Vitale 2002).
Current treatment
The mainstay of treatment of posterior uveitis is corticosteroids, 
which are administered in 3 forms: topically (most often 
used in conjunction with other forms), locally via sub-
Tenon’s or intravitreal injection, and systemically (Jabs et al 
2005). Each of these treatment modalities has strengths and International Journal of Nanomedicine 2007:2(1) 57
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weaknesses that must be weighed to individualize treatment 
for a particular patient. Topical steroid drops and ointment are 
primarily useful for anterior uveitis or panuveitis, as penetration 
into the posterior segment is minimal (Jabs et al 2005).
Local injection of long-acting steroids such as 
methylprednisolone or triamcinolone, however, results in 
therapeutic concentrations in the posterior segment and 
therefore can be useful for treatment of posterior uveitis in 
some individuals (Sabrosa and Pavésio 2000). The relatively 
low systemic concentration of steroids achieved by this method 
spares patients from the usual complications of steroid therapy, 
such as Cushingoid features, bone marrow suppression and 
infection, avascular necrosis, hyperglycemia, and osteopenia 
(Sabrosa and Pavésio 2000). Disadvantages to this form of 
therapy, however, include the necessity of repeated local 
injections as the steroid concentration in the posterior segment 
declines and the recurrence of inﬂ  ammation every 2–3 months 
(Jabs et al 2005). These patients may suffer poorer outcomes 
than patients treated with systemic steroids due to visual loss 
in the interval between steroid injections (Jabs et al 2005), as 
recurrences of inﬂ  ammation and repeated attacks may lead to 
cumulative damages and permanent visual compromise. In 
addition, intraocular steroid injections can lead to increased 
intraocular pressure, ptosis, strabismus, and carry a risk of 
globe penetration (Sabrosa and Pavésio 2000).
Many patients with posterior uveitis depend on systemic 
steroids to achieve long-term control of intraocular 
inﬂ  ammation, and this form of therapy is considered ﬁ  rst-
line for posterior non-infectious uveitis (Jabs et al 2005). 
Oral prednisone is most often used, starting at a dosage of 
1–2 mg/kg/day until inﬂ  ammation abates, and then tapered 
gradually to a maintenance level of 15 mg/day or less 
(Sabrosa and Pavésio 2000). However, patients often tolerate 
oral prednisone best with the lowest risk for experiencing 
side-effects if the maintenance dose is 10 mg/day or 
less. In cases of vision-threatening inﬂ  ammation, pulsed 
intravenous methylprednisolone of 1 g/day for 3 days can 
be used for rapid resolution, and patients may be switched 
to lower doses of oral prednisone thereafter (Sabrosa and 
Pavésio 2000). Due to the recurrent nature of the majority 
of uveitic entities, many patients must be maintained on 
high doses of long-term oral prednisone (>10 mg/day) in 
order to suppress active inﬂ  ammation. Unfortunately, this 
course of treatment can lead to numerous adverse effects, 
including Cushingoid features, hyperglycemia, osteopenia 
and osteoporosis, bone marrow suppression and infection, 
avascular necrosis, hypertension, insomnia, and psychosis, 
among others. While weight gain and Cushingoid features 
may not meet the standard of adverse events, they are quite 
difﬁ  cult for most patients to endure. On the other end of the 
continuum, however, avascular necrosis and osteoporosis can 
be debilitating and bone marrow suppression and infection 
may be life threatening. These conditions necessitate the 
cessation of corticosteroid therapy.
Additional immunomodulating drugs may be added to 
the corticosteroid regimen or used alone when steroids are 
not tolerated in order to control the inﬂ  ammation. There are 
three classes of immunomodulatory therapy (IMT) that are 
commonly used in the management of ocular inﬂ  ammatory 
diseases: antimetabolites, T-cell inhibitors, and alkylating 
agents. The common antimetabolites include methotrexate, 
azathioprine, and mycophenolate mofetil. Methotrexate is 
a folic acid analogue that inhibits dihydrofolate reductase, 
which is necessary for DNA and RNA synthesis. Its role in 
posterior uveitis is primarily for steroid-resistant pars plinitis 
and sympathetic ophthalmia (Sabrosa and Pavésio 2000). 
Methotrexate is given weekly; adverse effects include gastro-
intestinal upset, reversible hepatotoxicity, pulmonary ﬁ  brosis, 
and teratogenicity (Sabrosa and Pavésio 2000; Jabs et al 2005). 
Azathioprine is a purine analogue that has also been used for 
the treatment of ABD, in addition to Vogt-Koyanagi-Harada 
and sympathetic ophthalmia (Sabrosa and Pavésio 2000). 
Mycophenolate mofetil is also a purine synthesis inhibitor, 
originally developed for the prevention of kidney transplant 
rejection. It can be used for the treatment of posterior uveitis in 
patients intolerant to steroids, though it has its own treatment-
limiting side-effects, including diarrhea (Jabs et al 2005).
Among the T-cell inhibitors, cyclosporine, an inhibitor 
of the inﬂ  ammatory cytokine interleukin-2, has been shown 
to be effective in the treatment of ABD, though it is often 
combined with corticosteroids for optimal results (Sabrosa 
and Pavésio 2000). Its usefulness is limited by the common 
side-effects of nephrotoxicity and hypertension.
Cyclophosphamide, an alkylating agent used in the 
treatment of neoplastic disease, can be used for Wegener’s 
granulomatosis and necrotizing scleritis, though it is known 
to cause sterility and hemorrhagic cystitis, which may be 
associated with bladder cancer (Sabrosa and Pavésio 2000). 
Chlorambucil, another alkylating anti-neoplastic agent, has 
also been used in the treatment of posterior uveitis, including 
ABD (Sabrosa and Pavésio 2000). Although it shares some 
of the adverse effects of cyclophosphamide, including 
teratogenicity and sterility, it has not been related to cystitis 
or bladder cancer (Jabs et al 2005).International Journal of Nanomedicine 2007:2(1) 58
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Unfortunately, these systemic immunomodulating 
therapies share with prednisone many potential systemic 
side-effects including the risks of bone marrow suppression 
and the possibility of infection by opportunistic organisms. 
If only local therapy with periocular or intravitreal delivery 
of steroids is used in the management of uveitis without 
the use of systemic steroids and/or IMT, disease often 
occurs. Repeated bouts of inﬂ  ammatory episodes can lead 
to cumulative damage of ocular structures and functions, 
potentially leading to permanent visual loss. Thus, the 
risks of adverse events associated with prednisone and 
IMT have led to research efforts focused on developing 
effective local techniques of drug delivery that avoid the 
necessity of repeated intraocular injections and reduce the 
side-effects from systemic therapy, thus decreasing the risk 
for cumulative damage and visual loss.
Fluocinolone acetonide intravitreal 
implant: the ﬁ  rst FDA-approved 
drug for the treatment of uveitis
The beneﬁ  cial effects of the gancyclovir intravitreal implant 
device for CMV retinitis led investigators to explore the use 
of corticosteroid implants in the treatment of uveitis. The 
dexamethasone implant, detailed above, showed promise in a 
rabbit model of uveitis and proved to be effective at resolving 
a severe case of granulomatous iridocyclitis in a case report 
(Jaffe et al 2000b). Ten months after implantation of the device, 
however, the patient’s uveitis recurred, indicating the need 
for longer-acting implants (Jaffe et al 2000b). Such results 
led Jaffe and colleagues to examine ﬂ  uocinolone acetonide, 
a corticosteroid with 1/24 the solubility of dexamethasone 
in aqueous solution, which presumably would allow steroid 
release over a much longer time period (Jaffe et al 2000c).
Pre-clinical studies
To demonstrate the safety and feasibility of a ﬂ  uocinolone 
acetonide implant, Jaffe and colleagues constructed devices 
containing 15 mg of steroid and implanted them into the 
right eyes of 14 rabbits, using the fellow eyes as controls 
(Jaffe et al 2000c). Electroretinograms over a 54-week period 
showed no evidence of retinal toxicity, and histopathologic 
analysis of the implanted eyes was normal. The mean release 
rate from the devices was 3.26 μg/day, which remained 
relatively constant over the 54-week analysis period. Finally, 
throughout the study, there was no clinical evidence of 
toxicity by ophthalmoscopy. The authors estimated from the 
linear release kinetics that the 15-mg implant could last 18.6 
years in the rabbit eye and 2.7 years in the human eye, making 
it a potential candidate for the treatment of chronic uveitis.
Pharmacokinetics
A follow-up study of rabbits implanted with 0.5- and 2-mg 
implants found constant levels of ﬂ  uocinolone acetonide 
in the vitreous at all time points tested from 2 hours to 12 
months post-implantation, indicating zero-order kinetics 
(Driot et al 2004). A dose-concentration relationship was also 
demonstrated, with vitreous concentrations 7–8 times higher 
in rabbits ﬁ  tted with 2 mg implants compared with those with 
0.5 mg implants. Steroid concentrations in the retina and 
vitreous were considerably higher than those measured in 
the aqueous humor, indicating posterior localization. Urine 
and plasma levels of ﬂ  uocinolone were below the threshold 
of detection of 200 pg/mL, indicating the lack of systemic 
absorption.
The ﬁ  ndings have been conﬁ  rmed in human trials, where 
ﬂ  uocinolone was also undetectable in blood samples (Jaffe 
2006). In the rabbit trial, estimations of the implant lifespan 
were similar to that predicted by Jaffe et al (2000c), with 
approximately 38% of the steroid delivered after 1 year for 
the 0.5 mg implant and approximately 65% delivered in 
the 2 mg implant (Driot et al 2004). These results reinforce 
the local activity of the fluocinolone implant and the 
accompanying low risk of systemic adverse effects compared 
with current therapies.
Early clinical trials
To evaluate the safety and efﬁ  cacy of the ﬂ  uocinolone 
implant in humans, Jaffe and colleagues (2000a) recruited 5 
patients with severe uveitis involving the posterior segment 
who had previously responded well to corticosteroids. The 
study group included 3 patients with panuveitis, 1 with 
iridocyclitis and intermediate uveitis, and 1 with Behcet’s 
syndrome. Seven eyes of the 5 study patients were implanted 
with ﬂ  uocinolone acetonide intravitreal sustained-delivery 
devices and followed for an average of 10 months (Figure 1). 
All implanted eyes demonstrated stable or increased visual 
acuity, improving from a median of 20/200 to 20/30, and 
signiﬁ  cant reduction in corticosteroid requirements. Before 
implantation, all 7 eyes needed local steroid injections, 6 
required topical steroid drops, and 1 patient was treated 
with high-dose systemic steroids. After implantation of the 
devices, no patients needed periocular injections or topical 
steroids, and 1 patient used 10 mg prednisone systemically International Journal of Nanomedicine 2007:2(1) 59
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on alternating days to facilitate recovery of endogenous 
glucocorticoid production. No implanted eyes showed 
any signs of inﬂ  ammation during the study. Three of the 4 
non-implanted, intact fellow eyes (1 patient had undergone 
a previous enucleation), however, developed worsening 
inﬂ  ammation during the study period, including episodes 
of necrotizing retinitis and reactivated chorioretinitis. These 
results indicated that the ﬂ  uocinolone acetonide implant was 
effective at controlling posterior uveitis in steroid-responders 
during an average follow-up period of 10 months. One 
limitation of the study, the authors noted, was the unanswered 
question of whether non-steroid responders would experience 
uveitis regression with the ﬂ  uocinolone acetonide implant.
Increased intraocular pressure is a known complication 
of local corticosteroid use that limits the efﬁ  cacy of topical 
steroid drops and local injections. In eyes implanted with 
the steroid-releasing device, mean intraocular pressure rose 
from a baseline value of 13.1 mm Hg to 15.7 mm Hg at the 
end of the observation period. Although this difference was 
not statistically signiﬁ  cant, new pressure-lowering topical 
drops were needed in 4 of the 5 implanted eyes during the 
study, implying a relationship between device implantation 
and increased intraocular pressure.
In 2005, Jaffe and colleagues reported the results of a 
larger follow-up study to their pilot trial of the ﬂ  uocinolone 
acetonide implant. In this trial, the study population included 5 
eyes of 4 patients from the pilot study and added 31 eyes of 28 
new patients. The patients from the pilot study all received the 
2.1 mg device, and the new patients’ eyes were randomized 
to receive a 0.59 mg or 2.1 mg implant and observed for 
an average of 683 days (range 204–1817). Investigators 
remained blinded as to the dosage assignments at the time 
of manuscript preparation, so the combined results of the 2 
groups were presented. Inclusion criteria for the follow-up 
study included incomplete response or inability to tolerate 
adverse effects of corticosteroids or immunosuppressants, 
visual acuity of light perception or better, intraocular pressure 
less than or equal to 21 mm Hg, and a history of noninfectious 
posterior or intermediate uveitis.
Of the study participants, 38.9% were diagnosed with 
idiopathic panuveitis and 19.4% with sarcoidosis. Women 
represented a large majority of the study population at 80.6%. 
The principal outcome measures were inﬂ  ammation, visual 
acuity, anti-inﬂ  ammatory medication use, and safety.
A comparison of inflammation before and after 
surgery revealed a markedly decreased number of 
episodes with the ﬂ  uocinolone acetonide implant. In the 
12-month period while study eyes were treated with standard 
therapy, each eye averaged 2.5 inflammatory episodes. 
In contrast, only 5 inflammatory episodes were observed 
during the entire post-implant follow-up period–all of 
which occurred in the same 2 eyes. These 5 episodes all 
Figure 1 The ﬂ  uocinolone acetonide device is inserted into the vitreous cavity through a scleral incision and anchored with a suture.International Journal of Nanomedicine 2007:2(1) 60
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occurred at 29 months after device implantation or later, 
and no inﬂ  ammation was observed in the other 34 implanted 
eyes. Notably, non-implanted fellow eyes exhibited high 
rates of inﬂ  ammatory episodes. At 1 year after device 
implantation, inﬂ  ammation recurred in 9 of 23 eyes, and at 
24 months, 5 out of 15 eyes had inﬂ  ammatory episodes.
In addition to experiencing fewer inﬂ  ammatory episodes, 
implanted eyes demonstrated substantially improved visual 
acuity, starting at a baseline of +1.11 logMAR units and 
improving to +0.72 at 24 months and +0.81 at 30 months. 
Mean visual acuity improvement in implanted eyes was 0.44 
logMAR units between months 6 and 9, 0.47 from months 9 
to 18, and 0.68 from months 18 to 30. In contrast, the fellow 
eyes did not improve signiﬁ  cantly during the course of the 
trial, and by 6 months the implanted and fellow eyes did 
not statistically differ in visual acuity despite the fellow eye 
having signiﬁ  cantly better vision at baseline. Greater than 
90% of implanted eyes had stable or improved visual acuity 
during 2 years of follow up.
The proportion of patients requiring systemic 
corticosteroids or other immunosuppressive drugs declined 
signiﬁ  cantly from 53.1% at baseline to 44.4% at 12 months 
and 38.8% at 24 months. Of these patients, none required 
systemic medication for inﬂ  ammation in the implanted 
eye, but instead needed treatment for systemic disease 
or inﬂ  ammation in the fellow eye. In addition, the dose 
requirement decreased in 70% of patients receiving systemic 
medication at 12 months, and in 85% at 24 months.
Implanted eyes also saw considerable reduction in local 
corticosteroid injections following implantation. The average 
injection rate at baseline was 2.2 per eye per year, but after 
device insertion, no injections were required for the ﬁ  rst 24 
months of follow up. At 36 months the injection rate was 
0.03, increasing to 0.07 at 36 months. Topical corticosteroid 
drop use demonstrated a similar decline in implanted eyes, 
moving from 6.1 drops per patient per day at baseline to 
1.1 at 24 months and 0.3 at 30 months. The proportion of 
implanted eyes requiring drops decreased from 78.1% before 
implantation to 21% at 2 years.
The pilot study of the ﬂ  uocinolone acetonide implant 
demonstrated no statistically significant increase in 
intraocular pressure, but showed that an increased proportion 
of implanted eyes required pressure-lowering topical 
medication (Jaffe et al 2000a). Safety evaluation in the 
follow-up study mirrored these ﬁ  ndings, with a statistically 
insigniﬁ  cant increase in intraocular pressure in implanted 
eyes from 14 mm Hg at baseline to 18.8 mm Hg at 24 
months. Similarly to the pilot study, however, the proportion 
of implanted eyes requiring topical pressure-lowering drops 
increased from 11% at baseline to 56.1% between months 
18 and 27, when they needed a mean of 3.3 types of drops 
each. In addition to topical therapy, glaucoma ﬁ  ltering 
procedures were required to lower intraocular pressure in 
19.4% of implanted eyes during the study, compared with 
0% in fellow eyes.
Cataract development is a known complication of 
corticosteroids, but a high rate of prior cataract extraction in 
study patients made it difﬁ  cult to assess this relationship with 
the implant. Fifty percent of implanted eyes had undergone 
cataract surgery before entering the study and an additional 
27.7% had cataract surgery during the implantation procedure. 
Only 8 phakic eyes remained following implantation, and 4 of 
these underwent cataract extraction during the study. The only 
other complications observed during the study follow-up period 
were 7 cases of hypotony (19.4% of implanted eyes), of which 5 
resolved without treatment. No endophthalmitis, severe vitreous 
hemorrhage, or other complications were seen.
Fluocinolone acetonide uveitis
study group
In response to the positive results reported in the pilot and 
follow-up trials, a multi-centered, randomized controlled 
trial was designed to study the efﬁ  cacy and safety of the 
fluocinolone acetonide implant in a wider population. 
Patients were randomly assigned at study entry to a 2.1 mg 
implant, releasing 1.8–2.0 μg/day, or a 0.59 mg implant, 
releasing 0.4–0.5 μg/day. Patients would subsequently be 
followed for the lifespan of the implant, estimated to be 1000 
days for both dosages. Any inﬂ  ammatory recurrences were 
to be managed with local therapy (Jaffe et al 2006).
Eligible patients included those with 1 or more years 
of recurrent, non-infectious posterior uveitis who had 
either been treated with systemic medication for at least 
3 months or who had 2 or more recurrences in a 6 month 
period. Study participants were also required to have visual 
acuity of at least 15 letters on the Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart and a quiet eye at the 
time of implantation surgery. Patient were excluded from 
the study if their intraocular pressure was greater than 25 
on 2 or more pressure-lowering medications, if they had 
a history of uncontrolled intraocular pressure while using 
corticosteroids, or if they required systemic corticosteroids 
or other immunosuppressants for non-ocular disease. The 
primary outcome measure for the trial was a comparison of International Journal of Nanomedicine 2007:2(1) 61
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uveitis recurrence rates before and after device implantation. 
Secondary measures included improvement of visual acuity, 
adjunctive therapy requirement, and a comparison of uveitis 
recurrence rates in the implanted and fellow eyes.
A total of 278 patients at 27 clinical centers met all screening 
requirements and were randomized into treatment groups, 
including 110 receiving the 0.59 mg implant and 168 ﬁ  tted with 
the 2.1 mg device. The average age of study participants was 
43.5 years, ranging from 7 to 84. Bilateral disease was present 
in 77.3%, and 72.3% of study participants were female.
As the investigators remain masked to the treatment group 
assignment, the composite results are discussed. With 2 years 
of follow-up after implantation, the proportion of study eyes 
experiencing recurrence decreased considerably, from 59.7% 
in the 12 month period prior to implantation to 5.4% during 
the 12 months following surgery and 11.2% after 24 months 
of follow-up (Jaffe et al 2006). Conversely, the proportion 
of fellow eyes suffering inﬂ  ammatory episodes increased 
from 25.4% 1 year prior to study entry to 42.4% at 1 year 
and 50% at 2 years. Thus the ﬂ  uocinolone acetonide implant 
was signiﬁ  cantly more successful at treating posterior uve-
itis compared with standard therapy, according to the main 
outcome measure.
The secondary measures of the study, visual acuity and 
necessity of adjunctive therapy, further demonstrated the 
efﬁ  cacy of the ﬂ  uocinolone implant. Average ETDRS visual 
acuity improved 5.1 letters in implanted eyes, compared 
with a drop of 3.9 letters in non-implanted fellow eyes. The 
proportion of patients needing systemic corticosteroids or 
other immunosuppressive drugs dropped markedly from 
52.5% at study entry to 12.5% after 2 years of observation. 
The proportion of study eyes receiving local injections of 
corticosteroids to control intraocular inﬂ  ammation decreased 
from 68% in the 12 months before study entry to 9.7% during 
24 months following implantation. This is in contrast to the 
increase in injection rate in fellow eyes from 30.4% to 45.3%. 
Finally, a smaller proportion of implanted eyes required 
topical steroid treatment after implantation, 27.8%, compared 
with 35.7% at baseline. More fellow eyes required topical 
steroids, as the rate increased from 25.3% to 35.6%.
The early studies of the ﬂ  uocinolone acetonide implant 
found that eyes with the device required more topical 
pressure-lowering drops than before surgery, though the mean 
increase in intraocular pressure was not signiﬁ  cant. These 
ﬁ  ndings were paralleled in the multi-centered study, where 
the proportion of implanted eyes requiring pressure-lowering 
drops increased from 14% at baseline to 53.7% at 2 years after 
surgery. Additionally, 30.6% of implanted eyes underwent 
pressure-lowering ﬁ  ltration surgery during the course of the 
study. Interestingly, the proportion of non-implanted fellow 
eyes needing pressure-lowering drops also increased after 2 
years of follow-up, though noticeably less than study eyes, 
illustrating that eyes with ocular inﬂ  ammatory diseases are 
at risk for developing ocular hypertension and glaucoma. At 
the time of enrollment, 10.9% of fellow eyes needed pressure-
lowering drops, and this proportion increased to 20.2% at 
2 years, which was statistically signiﬁ  cant.
Unlike previous clinical trials of the ﬂ  uocinolone acetonide 
implant, the multi-centered study enrolled sufﬁ  cient patients 
to compare rates of cataract development in implanted and 
fellow eyes. Of implanted phakic eyes in a 1 year period 
following implantation, 27.3% developed cataract and all but 
2 (25.9%) underwent cataract extraction. This proportion was 
relatively high compared with fellow eyes, in which only 5.8% 
developed cataract and 3.2% underwent extraction surgery. 
After 2 years of follow-up, the rate of cataract development 
increased markedly to 89.4% in implanted eyes, compared to 
13.3% in fellow eyes. These results conﬁ  rm earlier hypotheses 
that the intravitreal implantation of a corticosteroid-releasing 
device would lead to a higher rate of cataract formation. 
In addition to the more common adverse effects of rising 
intraocular pressure and cataract development, a number of 
less common complications were observed during the post-
implant observation period, including hypotony in 6.1%, 
retinal detachment in 2.9%, endophthalmitis in 0.4%, and 
explantation at 2 years in 3.6% (Jaffe et al 2006).
Summary and discussion
As the result of several clinical trials demonstrating safety 
and efﬁ  cacy, the United States FDA approved the ﬂ  uocinolone 
acetonide intravitreal implant, 0.59 mg (Figure 2), as a single-
indication orphan drug for the treatment of non-infectious 
posterior uveitis in April 2005. It received fast-track status 
due to the lack of drugs currently on the market indicated 
speciﬁ  cally for posterior uveitis.
Comparison with current therapy
The mass of evidence produced by the clinical trials detailed 
above suggests that the ﬂ  uocinolone acetonide intravitreal 
implant can play a substantial role in the management of 
non-infectious posterior uveitis. It holds several advantages 
over current methods of corticosteroid delivery that may 
produce intolerable systemic side-effects or require frequent 
administration to maintain quiescence of inﬂ  ammation. International Journal of Nanomedicine 2007:2(1) 62
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Systemic corticosteroids – often the most effective, though 
suboptimal, treatment for posterior uveitis – produce adverse 
effects ranging from mild to extremely serious and life 
threatening.
The search for alternatives to long-term systemic 
corticosteroid use has produced several candidates 
with concurrent advantages and disadvantages. Topical 
corticosteroid therapy is a poor choice for posterior uveitis due 
to the low concentrations achieved in the posterior segment. 
Local sub-Tenon’s injections solve the concentration problem 
but only last a few months, necessitating several injections 
per year in order to keep inﬂ  ammation at bay. Additionally, 
with repeated injections, the risk of serious adverse effects, 
such as globe penetration or endophthalmitis, increases. 
Recurrent bouts of inﬂ  ammation between injections can lead 
to cumulative damage causing irreversible visual loss. The 
use of IMT as a steroid-sparing approach has been successful 
in controlling uveitis, but the patients are subjected to the 
potentially signiﬁ  cant side-effects of IMT.
The ﬂ  uocinolone acetonide implant effectively addresses 
many of the concerns presented by current therapies by 
providing long-term control of posterior segment inﬂ  ammation 
without the systemic complications of corticosteroids. In the 
studies detailed above, the rates of recurrence plummeted 
after insertion of the implant, and study eyes remained quiet 
for an extended period of time, demonstrating the efﬁ  cacy of 
the ﬂ  uocinolone device. In the long-term follow-up to their 
pilot study, Jaffe and colleagues did not observe a recurrence 
of posterior uveitis over a 24 month period in 36 implanted 
eyes (Jaffe et al 2005). During the same time period in the 
ongoing multi-centered trial, only 11.2% of implanted eyes 
had experienced a recurrence. These results demonstrate 
that greater than 88% of eyes receiving the implant could be 
inﬂ  ammation-free for 2 years without additional intervention–a 
signiﬁ  cant improvement over local injections, which may last 
only 2–3 months. In addition to a decrease in the recurrence 
of uveitis, both studies showed improved visual acuity in 
implanted eyes and decreased reliance on adjunctive therapy, 
including systemic steroids and local injections.
Adverse effects
The major adverse effect related to the implant, as 
demonstrated in clinical trials, is increased intraocular 
pressure, requiring patients to use pressure-lowering topical 
medications. In both the pilot studies and the randomized-
control trial, intraocular pressure in implanted eyes increased 
throughout the study, though these increases were not 
statistically signiﬁ  cant. A larger percentage of study patients 
did, however, require the addition of pressure-lowering drops 
after implantation. The proportion of eyes requiring drops 
Figure 2 The ﬂ  uocinolone acetonide (RetisertTM) sustained-release intravitreal implant, shown relative to the tip of a pencil.International Journal of Nanomedicine 2007:2(1) 63
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quadrupled in Jaffe and colleagues’ follow-up trial, from 
11% at baseline to 56.1% between months 18 and 27. Similar 
proportions were seen in the multi-centered trial, with 14% 
using drops at baseline, increasing to 53.7% at 24 months. 
Filtering procedures were required by 30.6% of implant 
patients in this study. These ﬁ  ndings are not unexpected, 
given the long-known association between corticosteroids 
and increased intraocular pressure, but they underscore the 
importance of using alternative therapy in patients with 
signiﬁ  cant glaucoma, refractory ocular hypertension, or a 
history of increased intraocular pressure response to steroids. 
However, the results of the randomized trial showed that 
the percentage of patients who require glaucoma surgery  at 
36 months is approximately 39.9% (authors’ unpublished 
data). Certainly, there has been an increase in the rates of 
glaucoma surgery needed from 24 to 36 months, but the rates 
are less than those seen from baseline to 12 months and 24 
months, which may reﬂ  ect the termination of drug release 
at approximately 30 months.
Uveitic eyes may be predisposed to increased intraocular 
pressure due to shifting fluid dynamics caused by 
inﬂ  ammation. Investigators have reported a 10% incidence 
of secondary glaucoma in uveitis, which is postulated to be 
caused by aqueous outﬂ  ow obstruction through the trabecular 
meshwork (Kuchtey et al 2005). Inﬂ  ammation of the ciliary 
body in uveitic eyes leads to underproduction of aqueous 
humor and decreased perfusion of the trabecular meshwork, 
which blocks the outﬂ  ow tract and raises intraocular pressure 
(Kuchtey et al 2005). Adding corticosteroids, which increase 
intraocular pressure by unclear mechanisms, exacerbates the 
situation in uveitic eyes that already have underperforming 
aqueous outﬂ  ow tracts (Kuchtey et al 2005). It has also 
been hypothesized that the implant may effectively control 
inﬂ  ammation and thus restore the normal aqueous production 
by the ciliary body (Jaffe et al 2005). In the setting of a 
chronically blocked outﬂ  ow tract, intraocular pressure can 
rise, requiring the use of pressure-lowering medications.
Cataracts are the other common adverse effect of 
the ﬂ  uocinolone acetonide implant. The rate of cataract 
formation was difﬁ  cult to determine in earlier studies due to 
a high proportion of pseudophakic eyes at study enrollment. 
Most patients had previously been treated with systemic 
or local corticosteroids that likely contributed to prior 
cataract formation. The multi-centered trial conducted by 
the Fluocinolone Acetonide Study Group found a notable 
disparity between implanted and fellow eyes, however, 
with 12 month post-implant cataract development rates of 
27.3% and 5.8% respectively. This rate is comparable to 
patients receiving oral prednisone for ocular inﬂ  ammation, 
in which cataracts developed in 6.4–38.7% (Carnahan and 
Goldstein 2000). At 24 months of follow-up, however, 
cataract extraction rates climbed to 89.4% in implanted 
eyes, compared with 13.3% in fellow eyes. These ﬁ  ndings 
indicate that worsening of cataracts is most likely in patients 
who were implanted with the ﬂ  uocinolone implant and that 
cataract extraction is necessary in a large proportion of phakic 
patients treated with the implant.
Studies involving patients receiving local corticosteroid 
injections have reported lower rates of cataract development, 
but these ﬁ  ndings are limited by shorter follow-up time and 
a low number of injections. A study of 53 patients with 
posterior ocular inﬂ  ammation who received an average of 2.5 
sub-Tenon’s steroid injections found a cataract development 
rate of 17.5% among previously clear lenses, however the 
follow-up period was only 12 months (Lafranco Dafﬂ  on 
et al 1999). Another study involving a single intravitreal 
injection of triamcinolone acetate reported a cataract 
development rate of 14.3% in eyes with previously clear 
lenses and a 5.9% progression rate among eyes that already 
showed lens changes (Kok et al 2005). Interestingly, eyes 
in which cataract developed had a mean follow-up time of 
17.1 months, compared with a follow-up period of only 7 
months for eyes without lens changes. This suggests that 
longer follow-up periods may reveal greater rates of cataract 
formation, making it difﬁ  cult to compare rates across studies 
with differing methodologies.
Role in future treatment of uveitis
The positive results reported in the pilot, follow-up, 
and multi-centered trials suggest that the ﬂ  uocinolone 
acetonide intravitreal implant may play a signiﬁ  cant role 
in the treatment of non-infectious posterior uveitis. The 
population that would most beneﬁ  t from the implant is likely 
to be patients requiring long-term systemic corticosteroids 
for posterior uveitis who become intolerant to the adverse 
effects of these drugs. As shown in the clinical trials, 
patients receiving the implant are usually able to discontinue 
systemic corticosteroids unless they are needed for systemic 
disease or inﬂ  ammation in the fellow eye. In addition to 
alleviating the negative effects of systemic steroids, the 
implant appears to achieve superior inﬂ  ammatory control 
compared with other methods of steroid delivery. The 
implant may also be an alternative for patients with unilateral 
or asymmetric posterior uveitis, in whom the dosage of International Journal of Nanomedicine 2007:2(1) 64
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systemic corticosteroids required for control of inﬂ  ammation 
in the fellow eye could be significantly reduced or 
discontinued. Contraindications for the implant include 
uveitis with infectious etiology, signiﬁ  cant glaucoma, 
refractory ocular hypertension, or a history of increased 
intraocular pressure in response to steroids.
Ongoing studies
The Fluocinolone Acetonide Uveitis Study Group will con-
tinue following the study patients in their multi-centered 
trial for an additional year, with ﬁ  nal results of the study 
to be published at that time. The National Eye Institute is 
recruiting patients for an ongoing phase IV trial studying the 
efﬁ  cacy of the ﬂ  uocinolone acetonide implant versus oral cor-
ticosteroids and immunosuppressive agents in the treatment 
of non-infectious posterior, intermediate, or panuveitis: the 
Multicenter Uveitis Steroid Treatment (MUST) trial seeks 
to enroll 400 patients and randomize them to the implant or 
standard systemic corticosteroids, with supplemental im-
munosuppressants as needed. Twenty centers in the United 
States and 1 in Canada are enrolling patients for the study, 
which is designed to follow patients over an extended pe-
riod of time. As this is the ﬁ  rst large-scale trial to directly 
compare the implant to standard therapy, its ﬁ  ndings have 
the potential to be inﬂ  uential in future therapeutic guidelines 
for posterior uveitis.
The potential of sustained-release devices in targeted 
delivery of pharmacologic agents is vast. In addition to 
corticosteroids for ocular inflammatory diseases, other 
classes of therapeutic agents such as antibodies for choroidal 
neovascularization can potentially be packaged, stored, and 
delivered using such technology. Moreover, current research 
also focuses on technology that will deliver therapeutic agents 
in a sustained fashion, but unlike the ﬂ  uocinolone implant, will 
not require a scleral incision to place the implant into the vitreous 
cavity. Rather, the implant, which may be self-dissolvable 
or replaceable, can be inserted as an in-ofﬁ  ce procedure, 
allowing the chronic delivery of medications through only a 
mildly invasive procedure.
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